FR23C1032I1 - Protéines de liaison à bcma (cd269/tnfrsf17) - Google Patents

Protéines de liaison à bcma (cd269/tnfrsf17)

Info

Publication number
FR23C1032I1
FR23C1032I1 FR23C1032C FR23C1032C FR23C1032I1 FR 23C1032 I1 FR23C1032 I1 FR 23C1032I1 FR 23C1032 C FR23C1032 C FR 23C1032C FR 23C1032 C FR23C1032 C FR 23C1032C FR 23C1032 I1 FR23C1032 I1 FR 23C1032I1
Authority
FR
France
Prior art keywords
tnfrsf17
binding proteins
bcma binding
bcma
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1032C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46148885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1032(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FR23C1032I1 publication Critical patent/FR23C1032I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR23C1032C 2011-05-27 2023-09-07 Protéines de liaison à bcma (cd269/tnfrsf17) Active FR23C1032I1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161490732P 2011-05-27 2011-05-27
US201261647196P 2012-05-15 2012-05-15
PCT/EP2012/059762 WO2012163805A1 (fr) 2011-05-27 2012-05-24 Protéines de liaison à bcma (cd269/tnfrsf17)
EP12723206.4A EP2714737A1 (fr) 2011-05-27 2012-05-24 Protéines de liaison à bcma (cd269/tnfrsf17)

Publications (1)

Publication Number Publication Date
FR23C1032I1 true FR23C1032I1 (fr) 2023-10-13

Family

ID=46148885

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1032C Active FR23C1032I1 (fr) 2011-05-27 2023-09-07 Protéines de liaison à bcma (cd269/tnfrsf17)

Country Status (37)

Country Link
US (1) US20140105915A1 (fr)
EP (4) EP2714737A1 (fr)
JP (6) JP6263467B2 (fr)
KR (1) KR101972446B1 (fr)
CN (2) CN103562225B (fr)
AR (1) AR086579A1 (fr)
AU (1) AU2012264890C1 (fr)
BR (1) BR112013028779B8 (fr)
CA (1) CA2833820C (fr)
CL (2) CL2013003373A1 (fr)
CO (1) CO6811809A2 (fr)
CR (1) CR20130624A (fr)
CY (2) CY2023019I2 (fr)
DK (1) DK3415531T5 (fr)
DO (1) DOP2013000280A (fr)
EA (2) EA201790330A1 (fr)
ES (1) ES2953190T3 (fr)
FI (2) FI3415531T3 (fr)
FR (1) FR23C1032I1 (fr)
HR (1) HRP20231066T1 (fr)
HU (2) HUE063461T2 (fr)
IL (2) IL228784B (fr)
LT (1) LT3415531T (fr)
MA (1) MA35208B1 (fr)
MX (1) MX351069B (fr)
MY (1) MY177970A (fr)
NL (1) NL301241I2 (fr)
PE (1) PE20141045A1 (fr)
PL (1) PL3415531T3 (fr)
PT (1) PT3415531T (fr)
RS (1) RS64791B1 (fr)
SG (1) SG194176A1 (fr)
SI (1) SI3415531T1 (fr)
TW (2) TWI609883B (fr)
UY (1) UY34101A (fr)
WO (1) WO2012163805A1 (fr)
ZA (1) ZA201308635B (fr)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148089A0 (en) 1999-08-17 2002-09-12 Biogen Inc Baff receptor (bcma), an immunorgulatory agent
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
PT3415531T (pt) * 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9765342B2 (en) 2012-04-11 2017-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
AU2013340799B2 (en) 2012-11-01 2018-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP2016507523A (ja) * 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
EP2762496A1 (fr) * 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
EP2762497A1 (fr) * 2013-02-05 2014-08-06 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
CA2900529A1 (fr) * 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Methodes de diagnostic, de pronostic et de surveillance ameliorees pour un myelome multiple, une leucemie lymphoide chronique et un lymphome non hodgkinien a lymphocytes b
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
GB2513405A (en) * 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
CA2916521C (fr) 2013-07-09 2023-03-07 Annexon, Inc. Anticorps anti-facteur du complement c1q et utilisations de ceux-ci
BR112016018100A2 (pt) 2014-02-07 2018-02-20 Univ Mcmaster acoplador antigênico de células t trifuncional, métodos e usos do mesmo
AU2015221933B2 (en) 2014-02-27 2019-09-12 Autolus Limited APRIL variants
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
RU2749041C2 (ru) * 2014-04-30 2021-06-03 Макс-Дельбрюк-Центрум Фюр Молекуляре Медицин Ин Дер Хельмхольтц - Гемайншафт Гуманизированные антитела против cd269 (bcma)
CA2951044C (fr) 2014-06-06 2023-10-03 Bluebird Bio, Inc. Compositions de lymphocytes t ameliorees
AU2015292811B2 (en) 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
EP3193915A1 (fr) 2014-07-21 2017-07-26 Novartis AG Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
NZ728555A (en) 2014-07-24 2024-07-26 2Seventy Bio Inc Bcma chimeric antigen receptors
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
ES2832711T3 (es) 2014-10-31 2021-06-11 Abbvie Biotherapeutics Inc Anticuerpos anti-CS1 y conjugados anticuerpo fármaco
EP3023437A1 (fr) 2014-11-20 2016-05-25 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP3029068A1 (fr) * 2014-12-03 2016-06-08 EngMab AG Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies
DK3628687T3 (da) 2014-12-12 2021-10-18 2Seventy Bio Inc Kimære bcma-antigenreceptorer
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
SG10201912823PA (en) * 2015-04-13 2020-02-27 Pfizer Therapeutic antibodies and their uses
US10294304B2 (en) * 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
EP3286211A1 (fr) 2015-04-23 2018-02-28 Novartis AG Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
MX2018001398A (es) * 2015-08-03 2018-05-28 Engmab Sarl Anticuerpos monoclonales contra bcma.
WO2017027392A1 (fr) 2015-08-07 2017-02-16 Novartis Ag Traitement du cancer à l'aide des protéines de récepteur cd3 chimères
AU2016347516A1 (en) * 2015-10-30 2018-05-10 Glaxosmithkline Intellectual Property Development Limited Prognostic method
KR20190008171A (ko) * 2015-11-13 2019-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-bcma 폴리펩티드 및 단백질
LT3380620T (lt) 2015-11-23 2024-09-10 Novartis Ag Optimizuoti lentivirusiniai pernešimo vektoriai ir jų panaudojimas
BR112018010360A2 (pt) 2015-11-24 2018-12-04 Annexon Inc fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
HUE064791T2 (hu) 2015-11-25 2024-04-28 Visterra Inc APRIL ellenes antitest molekulák és alkalmazásaik
EP4015537A1 (fr) * 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Traitements combinés, et utilisations et méthodes associées
WO2017099712A1 (fr) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Compositions de lymphocytes t améliorées
EP4219689A3 (fr) 2015-12-30 2023-12-20 Novartis AG Thérapies cellulaires effectrices immunitaires à efficacité améliorée
US11698369B2 (en) 2016-01-12 2023-07-11 Oncotracker, Inc. Methods for monitoring immune status of a subject
IL311107A (en) * 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
EP3423482A1 (fr) 2016-03-04 2019-01-09 Novartis AG Cellules exprimant de multiples molécules de récepteur d'antigène chimère (car) et leurs utilisations
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN117903307A (zh) 2016-04-01 2024-04-19 凯德药业股份有限公司 Bcma结合分子及其使用方法
EP3984559A1 (fr) 2016-04-01 2022-04-20 Kite Pharma, Inc. Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et leurs procédés d'utilisation
RS63735B1 (sr) 2016-04-01 2022-12-30 Kite Pharma Inc Himerni receptori i postupci njihove upotrebe
MX2018012615A (es) 2016-04-15 2019-05-30 Novartis Ag Composiciones y metodos para la expresion selectiva de proteinas.
IL263102B2 (en) 2016-05-20 2023-11-01 Harpoon Therapeutics Inc A serum albumin-binding protein with a single site
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3471773A4 (fr) 2016-06-21 2020-07-08 Teneobio, Inc. Anticorps se liant à cd3
CN110267677A (zh) 2016-08-01 2019-09-20 诺华股份有限公司 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
KR20190046854A (ko) * 2016-09-14 2019-05-07 얀센 바이오테크 인코포레이티드 Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도
PT4050034T (pt) 2016-09-14 2024-05-27 Teneoone Inc Anticorpos de ligação a cd3
EP4295918A3 (fr) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Anticorps bispécifiques contre bcma et cd3 et médicament dans le traitement du myélome multiple
KR20240005168A (ko) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포 조성물
WO2018111340A1 (fr) 2016-12-16 2018-06-21 Novartis Ag Procédés de détermination de la puissance et de la fonction proliférative de lymphocytes t à récepteur antigénique chimérique (car)
IL300729A (en) * 2016-12-21 2023-04-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
CN108341872B (zh) * 2017-01-23 2020-05-19 科济生物医药（上海）有限公司 靶向bcma的抗体及其应用
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018144535A1 (fr) 2017-01-31 2018-08-09 Novartis Ag Traitement du cancer à l'aide de protéines chimères du récepteur de lymphocytes t ayant de multiples spécificités
WO2018151836A1 (fr) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Traitements d'association pour le traitement de cancers associés à bcma et de troubles auto-immuns
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
DK3589655T3 (da) 2017-02-28 2022-11-28 Affimed Gmbh Tandem diabody til cd16a målrettet nk-celle optagelse
WO2018160731A1 (fr) 2017-02-28 2018-09-07 Novartis Ag Compositions d'inhibiteur shp et utilisations pour une thérapie de récepteur d'antigène chimère
CN108624549B (zh) * 2017-03-23 2020-11-20 上海奥浦迈生物科技有限公司 一种cho dg44培养基及其应用
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
WO2018209298A1 (fr) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Protéines de liaison à la mésothéline
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
WO2018231949A1 (fr) * 2017-06-14 2018-12-20 Dana-Farber Cancer Institute, Inc. Nanoparticules dirigées contre un antigène de maturation des lymphocytes b (bcma)
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2018237006A1 (fr) 2017-06-20 2018-12-27 Teneoone, Inc. Anticorps uniquement à chaînes lourdes anti-bcma
KR20200035066A (ko) * 2017-08-01 2020-04-01 메디뮨 엘엘씨 Bcma 단클론 항체-약물 접합체
CN111107874A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
WO2019053611A1 (fr) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Polythérapie pour le traitement du cancer
CN111094353A (zh) 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
WO2019067677A1 (fr) * 2017-09-29 2019-04-04 Cell Design Labs, Inc. Procédés de fabrication de récepteurs d'antigènes chimériques anti-cd307e et anti-bcma bispécifiques et leurs utilisations
JP7137619B2 (ja) * 2017-09-29 2022-09-14 モガム・インスティテュート・フォー・バイオメディカル・リサーチ Ｂｃｍａに対して高い親和性を有する抗ｂｃｍａ抗体およびそれを含むがんの処置のための医薬組成物
JP7227630B2 (ja) 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
CN111630070B (zh) 2017-10-13 2024-07-30 哈普恩治疗公司 三特异性蛋白质及使用方法
AU2018346955B2 (en) 2017-10-13 2024-08-29 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
EP3697436A1 (fr) 2017-10-18 2020-08-26 Novartis AG Compositions et méthodes pour la dégradation sélective d'une protéine
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019089798A1 (fr) 2017-10-31 2019-05-09 Novartis Ag Compositions anti-car et procédés
WO2019089969A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
GB201720426D0 (en) * 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
KR20200079511A (ko) 2017-11-01 2020-07-03 허밍버드 바이오사이언스 홀딩스 피티이. 엘티디. Cd47 항원-결합 분자
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
US11629183B2 (en) 2017-12-29 2023-04-18 University Of Florida Research Foundation, Inc. Monoclonal antibodies targeting microtubule-binding domain of tau protein and methods of detecting tau protein in vivo
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
WO2019152660A1 (fr) 2018-01-31 2019-08-08 Novartis Ag Polythérapie utilisant un récepteur antigénique chimérique
WO2019149269A1 (fr) * 2018-02-01 2019-08-08 信达生物制药(苏州)有限公司 Fragment variable à chaîne unique anti-antigène de maturation des lymphocytes b (bcma) entièrement humain, et application associée
JP6968389B2 (ja) * 2018-02-01 2021-11-17 南京馴鹿医療技術有限公司 Ｂｃｍａに結合するキメラ抗原受容体（ｃａｒ）及びその応用
EP3752203A1 (fr) 2018-02-13 2020-12-23 Novartis AG Thérapie par récepteur antigénique chimérique en combinaison avec il-15 r et il15
EP3755718A1 (fr) * 2018-02-21 2020-12-30 Celgene Corporation Anticorps de liaison à bcma et leurs utilisations
CN112204052A (zh) * 2018-04-05 2021-01-08 诺华股份有限公司 针对癌症的三特异性结合分子及其用途
CN110372796B (zh) * 2018-04-12 2023-05-02 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
EP3774914A2 (fr) 2018-04-13 2021-02-17 Affimed GmbH Constructions de fusion d'anticorps entrant en contact avec des cellules nk
EP3784351A1 (fr) 2018-04-27 2021-03-03 Novartis AG Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN112105420A (zh) 2018-05-11 2020-12-18 克里斯珀医疗股份公司 用于治疗癌症的方法和组合物
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
EP3802825A1 (fr) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions et procédés d'immuno-oncologie
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SG11202100883SA (en) * 2018-08-08 2021-02-25 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3844265A2 (fr) 2018-08-31 2021-07-07 Novartis AG Procédés de fabrication de cellules exprimant un récepteur d'antigène chimère
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
AR116548A1 (es) * 2018-09-28 2021-05-19 Amgen Inc Anticuerpos contra bcma soluble
US12116415B2 (en) 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
CA3118191A1 (fr) 2018-10-31 2020-05-07 Glaxosmithkline Intellectual Property Development Limited Procedes de traitement du cancer
WO2020088164A1 (fr) * 2018-11-01 2020-05-07 山东新时代药业有限公司 Anticorps bispécifique et son utilisation
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
WO2020160375A1 (fr) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Polythérapies contre le cancer faisant intervenir de la belantamab mafodotine et un anticorps anti-ox40, utilisations et méthodes associées
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN113412127A (zh) 2019-02-25 2021-09-17 诺华股份有限公司 用于病毒递送的介孔二氧化硅颗粒组合物
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
WO2020210678A1 (fr) 2019-04-12 2020-10-15 Novartis Ag Procédés de fabrication de cellules exprimant un récepteur antigénique chimérique
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
MX2021013359A (es) 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
TW202100184A (zh) 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體－藥物結合物及使用方法
WO2020237078A1 (fr) * 2019-05-22 2020-11-26 The Board Of Trustees Of The Leland Stanford Junior University Conjugués médicamenteux et leurs méthodes d'utilisation
AU2020284723A1 (en) * 2019-05-31 2022-01-27 Dana-Farber Cancer Institute, Inc. Combination therapy
MX2021015337A (es) 2019-06-14 2022-01-18 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
AU2020322588A1 (en) 2019-07-30 2022-02-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof
CA3146471A1 (fr) * 2019-08-06 2021-02-11 James K. Kranz Compositions comprenant des proteines liant l'antigene anti-bcma pour le traitement des maladies ou des troubles medies par l'antigene de maturation des lymphocytes b
CN112409482B (zh) * 2019-08-20 2022-08-26 杭州尚健生物技术有限公司 Bcma抗体
US20240052048A1 (en) 2019-10-10 2024-02-15 Suzhou Qin Pharmaceuticals Co., Ltd. Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity
BR112022010206A2 (pt) 2019-11-26 2022-11-29 Novartis Ag Receptores de antígeno quiméricos e usos dos mesmos
KR20220104783A (ko) * 2019-11-26 2022-07-26 상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드 Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질
CA3165399A1 (fr) 2019-12-20 2021-06-24 Novartis Ag Utilisations d'anticorps anti-tgf-betas et inhibiteurs de point de controle pour le traitement des maladies proliferatives
EP4085076A4 (fr) * 2020-01-03 2024-01-24 Biosion, Inc. Anticorps se liant à bcma et leurs utilisations
KR20220012314A (ko) * 2020-01-03 2022-02-03 살루브리스 (청두) 바이오테크 코., 리미티드 Bcma에 결합하는 항체 및 그의 용도
CN111234020B (zh) * 2020-01-23 2020-10-23 和铂医药(苏州)有限公司 一种bcma结合蛋白及其制备方法和应用
CA3167689A1 (fr) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Traitements combines et utilisations et methodes associees
CN113248611A (zh) * 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
BR112022017148A2 (pt) 2020-02-27 2022-11-08 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
JP2023515211A (ja) 2020-02-27 2023-04-12 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
BR112022022800A2 (pt) 2020-05-11 2022-12-13 Janssen Biotech Inc Métodos para tratamento de mieloma múltiplo
EP4165169A1 (fr) 2020-06-11 2023-04-19 Novartis AG Inhibiteurs de zbtb32 et leurs utilisations
CN115850484A (zh) * 2020-06-18 2023-03-28 重庆精准生物技术有限公司 一种靶向cd70的单链抗体及其应用
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
EP4199960A2 (fr) 2020-08-21 2023-06-28 Novartis AG Compositions et méthodes pour la génération in vivo de cellules exprimant car
TW202233677A (zh) 2020-11-02 2022-09-01 新加坡商蜂鳥生物科技私人有限公司 Bcma/taci抗原結合分子
CA3198996A1 (fr) 2020-11-24 2022-06-02 Matthew T. Burger Conjugues anticorps-medicament inhibiteurs de bcl-xl et leurs procedes d'utilisation
AU2021412988A1 (en) 2020-12-31 2023-06-15 Sana Biotechnology, Inc. Methods and compositions for modulating car-t activity
TW202246351A (zh) * 2021-02-08 2022-12-01 美商恩格姆生物製藥公司 Htra1結合劑及其使用方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4330381A1 (fr) 2021-04-27 2024-03-06 Novartis AG Système de production de vecteurs viraux
IL308637A (en) 2021-05-19 2024-01-01 Sana Biotechnology Inc Primary hypoimmunogenic T cells are RHD negative
KR20240013135A (ko) 2021-05-27 2024-01-30 사나 바이오테크놀로지, 인크. 조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포
BR112023024804A2 (pt) 2021-05-28 2024-02-15 Glaxosmithkline Ip Dev Ltd Terapias de combinação para tratar câncer
CA3173810A1 (fr) 2021-06-01 2022-12-01 Andreas Bader Coupleurs d'antigene de lymphocytes t de claudine 18.2 et leurs utilisations
KR20240021289A (ko) 2021-06-24 2024-02-16 엑사이트 바이오파마 리미티드 Bcma 및 cd3에 결합하는 이중특이성 항체 및 그 제조 방법과 응용
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
EP4370544A2 (fr) 2021-07-14 2024-05-22 Sana Biotechnology, Inc. Expression modifiée d'antigènes liés au chromosome y dans des cellules hypo-immunogènes
WO2023012669A2 (fr) 2021-08-03 2023-02-09 Glaxosmithkline Intellectual Property Development Limited Compositions biopharmaceutiques et procédé de cartographie peptidique de marquage isotopique stable
JP2024528981A (ja) 2021-08-04 2024-08-01 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ４標的化ウイルスベクターの使用
MX2024001443A (es) 2021-08-11 2024-05-15 Sana Biotechnology Inc Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
CN117858901A (zh) 2021-08-20 2024-04-09 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
WO2023057893A1 (fr) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Polythérapies pour le traitement du cancer
WO2023069790A1 (fr) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Procédés de modification de lymphocytes t allogéniques avec un transgène dans un locus de tcr et compositions et procédés associés
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
AU2022382988A1 (en) * 2021-11-04 2024-05-16 Dana-Farber Cancer Institute, Inc. Developing inducible cluster chimeric antigen receptor (ccar) constructs
WO2023104138A1 (fr) * 2021-12-09 2023-06-15 江苏先声药业有限公司 Anticorps anti-bcma et son utilisation
WO2023115041A1 (fr) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Glycoprotéines de fixation de paramyxoviridae modifiées
EP4448549A2 (fr) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Glycoprotéines de fusion de paramyxoviridae modifiées
KR20240137574A (ko) 2021-12-23 2024-09-20 사나 바이오테크놀로지, 인크. 자가면역 질환 치료를 위한 키메라 항원 수용체[chimeric antigen receptor, car] t 세포 및 관련 방법
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
CN118591560A (zh) 2022-01-25 2024-09-03 葛兰素史密斯克莱知识产权发展有限公司 癌症的组合疗法
WO2023150518A1 (fr) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Vecteurs lentiviraux ciblant cd3 et leurs utilisations
WO2023150647A1 (fr) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Procédés d'administration et de dosage répétés de particules lipidiques ou de vecteurs viraux et systèmes et utilisations connexes
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
AU2023236386A1 (en) 2022-03-18 2024-10-10 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2023214325A1 (fr) 2022-05-05 2023-11-09 Novartis Ag Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2
WO2023232911A1 (fr) * 2022-05-31 2023-12-07 Oncopeptides Innovation 1 Ab Nouveaux polypeptides
WO2024007020A1 (fr) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combinaison de cellules tueuses naturelles (nk) modifiées et d'une thérapie par anticorps et méthodes associées
WO2024026377A1 (fr) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Procédés de transduction utilisant un vecteur viral et des inhibiteurs de facteurs de restriction antiviraux
WO2024064838A1 (fr) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Particules lipidiques comprenant des glycoprotéines fixant des paramyxovirus variants et leurs utilisations
WO2024081820A1 (fr) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Particules virales ciblant des cellules souches hématopoïétiques
WO2024089639A1 (fr) 2022-10-26 2024-05-02 Novartis Ag Formulations lentivirales
WO2024119157A1 (fr) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation
WO2024121711A1 (fr) 2022-12-05 2024-06-13 Glaxosmithkline Intellectual Property Development Limited Méthodes de traitement au moyen d'antagonistes d'antigène de maturation des lymphocytes b

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP0871490B1 (fr) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Segments de liaison hydrazone ramifies
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
IL148089A0 (en) * 1999-08-17 2002-09-12 Biogen Inc Baff receptor (bcma), an immunorgulatory agent
CN101371923B (zh) * 1999-08-17 2013-04-17 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US6573074B2 (en) 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
WO2002020565A2 (fr) 2000-09-08 2002-03-14 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
AR030612A1 (es) 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
AU2002238052A1 (en) * 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ES2337986T3 (es) 2001-08-10 2010-05-03 Aberdeen University Dominios de union de antigenos de peces.
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1391213A1 (fr) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
ATE416190T1 (de) 2003-07-04 2008-12-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
CA2552435A1 (fr) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibiteurs des recepteurs du facteur de croissance endothelial vasculaire de type 2
AU2004315198A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of BCMA and uses thereof
EP1776385A1 (fr) 2004-07-21 2007-04-25 Glycofi, Inc. Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2
JP2008525002A (ja) * 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
WO2007011041A1 (fr) 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. Composition d'anticorps génétiquement modifié
MY150643A (en) * 2006-06-22 2014-02-14 Genentech Inc Methods and compositions for targeting hepsin
ZA200900836B (en) * 2006-08-28 2010-05-26 Ares Trading Sa Process for the purification of FC-fusion proteins
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
CA2710912A1 (fr) * 2008-01-15 2009-07-23 F. Hoffmann-La Roche Ag Anticorps afucosyles contre ccr5 et leurs utilisations
PL2406284T3 (pl) * 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
WO2011108008A2 (fr) * 2010-03-04 2011-09-09 Transgene Biotek Ltd. Anticorps tbl-cln1 pour une élimination de cellules cancéreuses par induction ciblée d'apoptose, de cdc (cytotoxicité dépendante du complément) et d'adcc (cytotoxicité cellulaire dépendante des anticorps)
EP2640750A1 (fr) * 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents et méthodes de traitement de maladies qui sont corrélées à une expression de bcma
PT3415531T (pt) * 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма

Also Published As

Publication number Publication date
DK3415531T3 (da) 2023-09-18
JP2022033797A (ja) 2022-03-02
DOP2013000280A (es) 2014-04-30
FIC20230029I1 (fi) 2023-09-07
IL255253A0 (en) 2017-12-31
ES2953190T3 (es) 2023-11-08
LT3415531T (lt) 2023-09-25
HUS2300027I1 (hu) 2023-12-28
HRP20231066T1 (hr) 2023-10-27
JP2014520088A (ja) 2014-08-21
CY2023019I1 (el) 2024-02-16
NL301241I2 (nl) 2023-10-26
JP2019147816A (ja) 2019-09-05
EP2714737A1 (fr) 2014-04-09
EA201391457A1 (ru) 2014-04-30
CA2833820A1 (fr) 2012-12-06
CY2023019I2 (el) 2024-02-16
JP2018087190A (ja) 2018-06-07
HUE063461T2 (hu) 2024-01-28
CN106279418A (zh) 2017-01-04
FI3415531T3 (fi) 2023-09-07
SI3415531T1 (sl) 2023-12-29
CL2013003373A1 (es) 2014-07-25
ZA201308635B (en) 2021-05-26
KR20140036272A (ko) 2014-03-25
AU2012264890C1 (en) 2016-03-10
PE20141045A1 (es) 2014-09-10
CA2833820C (fr) 2019-10-29
PL3415531T3 (pl) 2024-02-26
AU2012264890B2 (en) 2015-10-15
WO2012163805A1 (fr) 2012-12-06
SG194176A1 (en) 2013-12-30
KR101972446B1 (ko) 2019-04-25
MX351069B (es) 2017-09-29
EP3415531A1 (fr) 2018-12-19
NZ616433A (en) 2016-04-29
NL301241I1 (fr) 2023-09-13
TW201311722A (zh) 2013-03-16
MX2013013942A (es) 2014-05-21
RS64791B1 (sr) 2023-11-30
CY1126300T1 (el) 2024-02-16
TWI644924B (zh) 2018-12-21
IL228784B (en) 2018-03-29
EA028220B1 (ru) 2017-10-31
EP4338754A2 (fr) 2024-03-20
TW201811831A (zh) 2018-04-01
UY34101A (es) 2013-01-03
EP3693394A1 (fr) 2020-08-12
CN103562225A (zh) 2014-02-05
EP4338754A3 (fr) 2024-07-10
CL2016002585A1 (es) 2017-05-19
CN103562225B (zh) 2016-09-28
MA35208B1 (fr) 2014-06-02
TWI609883B (zh) 2018-01-01
JP6263467B2 (ja) 2018-01-17
EA201790330A1 (ru) 2018-02-28
JP7018910B2 (ja) 2022-02-14
CO6811809A2 (es) 2013-12-16
MY177970A (en) 2020-09-28
DK3415531T5 (da) 2024-09-23
US20140105915A1 (en) 2014-04-17
EP3415531B1 (fr) 2023-09-06
JP2024096908A (ja) 2024-07-17
JP2023085488A (ja) 2023-06-20
BR112013028779B1 (pt) 2021-01-05
BR112013028779B8 (pt) 2021-04-20
PT3415531T (pt) 2023-09-12
CR20130624A (es) 2014-02-04
BR112013028779A2 (pt) 2017-08-01
AU2012264890A1 (en) 2013-05-09
IL228784A0 (en) 2013-12-31
AR086579A1 (es) 2014-01-08
JP7260621B2 (ja) 2023-04-18
JP7475515B2 (ja) 2024-04-26

Similar Documents

Publication Publication Date Title
FR23C1032I1 (fr) Protéines de liaison à bcma (cd269/tnfrsf17)
LTC2521568I2 (lt) Plazmos kalikreiną surišantys baltymai
IL271804A (en) Mice producing binding proteins containing VL domains
IL259921B (en) A new stabilizing factor for pharmaceutical proteins
HK1212711A1 (zh) 抗原結合蛋白
DK2857420T3 (da) Målvævsspecifikt antigenbindende molekyle
BR112013014278A2 (pt) proteínas de ligação a tnf-a
DK2563400T3 (da) Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion
DK2850103T3 (da) ST2-antigenbindende proteiner
BR112013023611A2 (pt) instrumentos de grampeamento cirúrgico
DK3118221T3 (da) Proteiner
BR112013030352A2 (pt) proteínas de ligação do receptor fc
DK3431492T3 (da) Humane cd30-ligandantigen-bindende proteiner
BR112013015602A2 (pt) nova composição farmacèutica
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
BR112013007715A2 (pt) aparelho de processamento de informação
BR112013008074A2 (pt) combinações farmacêuticas
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina
DK2752424T3 (da) Glycosyleret somatostatin og lægemiddelsammensætning, der indeholder det
EP2593472A4 (fr) Protéines ancestrales
DE102011052996A8 (de) Informationsverarbeitungsvorrichtung
IT1399449B1 (it) Libretto medico
UA23277S (uk) Розсів лабораторний універсальний рлу-1
BR112013014399A2 (pt) mecanismo antitorque modular
UA21154S (uk) Етикетка для фармацевтичного засобу